Clinical Trial Update: A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of sotorasib (AMG 510) in KRAS G12C-mutant advanced solid tumo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Lumykras (sotorasib)

Snippet

Sponsor: Amgen | Conditions: KRAS p.G12C Mutant Advanced Solid Tumors | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING